☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
mNSCLC
Takeda Presents Results of Mobocertinib in P-I/II Study for Patients with EGFR Exon20 Insertion+ mNSCLC
May 20, 2021
Eli Lilly Reports Positive Results of Cyramza (ramucirumab) in P-III RELAY Study for mNSCLC
March 12, 2019
Pfizer's Vizimpro (Dacomitinib) Receives the US FDA Approval for 1L Treatment of mNSCLC with Epidermal Growth Factor Receptor (EGF...
September 28, 2018
Merck's Keytruda (pembrolizumab) Receives Expanded Label Approval for 1L nonsq. mNSCLC- with No EGFR and ALK Genomic Tumor
August 21, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.